Attached files

file filename
EX-32.1 - EX-32.1 - Aligos Therapeutics, Inc.d96959dex321.htm
EX-31.2 - EX-31.2 - Aligos Therapeutics, Inc.d96959dex312.htm
EX-31.1 - EX-31.1 - Aligos Therapeutics, Inc.d96959dex311.htm
10-Q - 10-Q - Aligos Therapeutics, Inc.d96959d10q.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Aligos Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: November 25, 2020     By:   /s/ Lesley Ann Calhoun
      Lesley Ann Calhoun
      Chief Financial Officer